Kura Oncology Announces Commencement of Public Offering of Common Stock
May 05 2020 - 3:01PM
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage
biopharmaceutical company committed to realizing the promise of
precision medicines for the treatment of cancer, today announced
that it has commenced an underwritten public offering, subject to
market and other conditions, to issue and sell shares of its common
stock. In connection with the offering, Kura expects to grant
the underwriters a 30-day option to purchase up to an additional
15% of the shares of common stock offered in the public
offering. There can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the
offering.
SVB Leerink, Cowen and Credit Suisse are acting
as joint bookrunning managers in the offering.
The securities described above are being offered
by Kura pursuant to a shelf registration statement on Form S-3,
including a base prospectus, that was previously filed by Kura with
the Securities and Exchange Commission (the “SEC”) and that was
declared effective on August 28, 2019. A preliminary
prospectus supplement and accompanying prospectus relating to the
offering will be filed with the SEC and will be available for free
on the SEC’s website located at http://www.sec.gov. Copies of
the preliminary prospectus supplement and the accompanying
prospectus relating to the offering, when available, may be
obtained from: SVB Leerink LLC, Attention: Syndicate Department,
One Federal Street, 37th Floor, Boston, MA 02110, by telephone at
(800) 808-7525, ext. 6218, or by email at syndicate@svbleerink.com;
Cowen and Company, LLC c/o Broadridge Financial Services, 1155 Long
Island Avenue, Edgewood, NY 11717, or by email at
PostSaleManualRequests@broadridge.com, or by phone at (833)
297-2926; or Credit Suisse Securities (USA) LLC, Attention:
Prospectus Department, Eleven Madison Avenue, 3rd Floor,
New York, NY 10010, or by telephone at (800) 221-1037, or by
email at usa.prospectus@credit-suisse.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy these securities,
nor shall there be any sale of these securities in any state or
other jurisdiction in which such offer, solicitation or sale would
be unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.
About Kura Oncology
Kura Oncology is a clinical-stage
biopharmaceutical company committed to realizing the promise of
precision medicines for the treatment of cancer. Kura’s pipeline
consists of two wholly-owned small molecule drug candidates that
target cancer signaling pathways where there is a strong scientific
and clinical rationale to improve outcomes by identifying those
patients most likely to benefit from treatment. Kura’s most
advanced drug candidate is tipifarnib, a potent, selective and
orally bioavailable farnesyl transferase inhibitor currently in a
registration-directed trial in patients with recurrent or
metastatic HRAS mutant head and neck squamous cell carcinoma
(HNSCC). Kura’s pipeline is also highlighted by KO-539, a
potentially first-in-class, potent and selective inhibitor of the
menin-MLL protein-protein interaction currently in a Phase 1/2A
clinical trial in patients with relapsed/refractory AML.
Forward-Looking Statements
Statements contained in this press release
regarding matters that are not historical facts are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Such
forward-looking statements include, without limitation, statements
about Kura’s expectations regarding the completion and timing of
the proposed offering, and its expectations with respect to
granting the underwriters a 30-day option to purchase additional
shares. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Words such
as “believes,” “anticipates,” “plans,” “expects,” “intends,”
“will,” “goal,” “potential” and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are based upon Kura’s current expectations and involve
assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events could
differ materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties, which
include, without limitation, risks associated with market
conditions and the satisfaction of closing conditions related to
the proposed public offering, risks and uncertainties associated
with Kura’s business and finances in general, risks associated with
the COVID-19 global pandemic, and the other risks described in
Kura’s quarterly report on Form 10-Q for the quarterly period ended
March 31, 2020 and other filings with the SEC. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Kura undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
Contacts
Company:Pete De SpainVice President, Investor Relations
&Corporate Communications(858)
500-8803pete@kuraoncology.com
Investors:Robert H. UhlManaging DirectorWestwicke ICR(858)
356-5932robert.uhl@westwicke.com
Media:Jason SparkManaging DirectorCanale Communications(619)
849-6005jason@canalecomm.com
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Apr 2023 to Apr 2024